BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37574339)

  • 1. Cost and effectiveness analyses of the anti-osteoporosis medication in patients with hip fracture in Taiwan: A population-based national claims database analysis.
    Wang CY; Wu CH; Chen HM; Lin JW; Hsu CC; Chang YF; Tai TW; Fu SH; Hwang JS
    J Formos Med Assoc; 2023; 122 Suppl 1():S92-S100. PubMed ID: 37574339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2023 Jan; 166():116605. PubMed ID: 36347433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the Requirement of Bone Mineral Density Evidence on Utilization of Anti-osteoporosis Medications, Clinical Outcome and Medical Expenditures of Patient With Hip Fracture in Taiwan.
    Wang CY; Fu SH; Hung CC; Yang RS; Lin JW; Chen HM; Hsiao FY; Shen LJ
    Int J Health Policy Manag; 2022 Apr; 11(4):470-478. PubMed ID: 33059424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2022 Jul; 160():116396. PubMed ID: 35351673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of anti-osteoporosis medications initiation after a hip fracture affects the risk of subsequent fracture: A nationwide cohort study.
    Wang CY; Fu SH; Yang RS; Chen LK; Shen LJ; Hsiao FY
    Bone; 2020 Sep; 138():115452. PubMed ID: 32464276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eleven years secular trend of the initiation of anti-osteoporosis medications and subsequent fractures in Taiwan: From 2008 to 2018.
    Yang TH; Wang CY; Fu SH; Chan DC; Chen HM; Lin JW; Huang CF; Yang JJ; Wu CH; Hwang JS; Yang RS
    J Formos Med Assoc; 2023; 122 Suppl 1():S36-S44. PubMed ID: 37280138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visualisation of the unmet treatment need of osteoporotic fracture in Taiwan: A nationwide cohort study.
    Wang CY; Fu SH; Huang CC; Hung CC; Yang RS; Hsiao FY
    Int J Clin Pract; 2018 Oct; 72(10):e13246. PubMed ID: 30144247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of anti-osteoporosis medications on total hip arthroplasty risks in osteoporotic patients with hip osteoarthritis in Taiwan: a nationwide cohort study.
    Hung CC; Wang CY; Fu SH; Yang RS; Hsiao FY
    Arch Osteoporos; 2018 Oct; 13(1):107. PubMed ID: 30306268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Interrupted Time Series Analysis of Long-term Direct Medical Costs in Patients With Hip Fractures and a Matched Cohort: A Large-database Study.
    Jang SY; Lee JW; Kim KJ; Kim HY; Choy WS; Cha Y
    Clin Orthop Relat Res; 2022 May; 480(5):891-902. PubMed ID: 34807010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
    Lin SY; Chen YM; Chen WJ; Li CY; Ku CK; Chen CH; Chien LN
    Arch Osteoporos; 2022 Jul; 17(1):94. PubMed ID: 35840845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of hip fractures in patients with dementia: a nationwide population-based study.
    Wang HK; Hung CM; Lin SH; Tai YC; Lu K; Liliang PC; Lin CW; Lee YC; Fang PH; Chang LC; Li YC
    BMC Neurol; 2014 Sep; 14():175. PubMed ID: 25213690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between osteoporosis medications and lowered all-cause mortality after hip or vertebral fracture in older and oldest-old adults: a nationwide population-based study.
    Li CC; Hsu JC; Liang FW; Chang YF; Chiu CJ; Wu CH
    Aging (Albany NY); 2022 Mar; 14(5):2239-2251. PubMed ID: 35232893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The real-world adherence of the first-line anti-osteoporosis medications in Taiwan: Visualize the gap between reality and expectations.
    Lee CC; Fu SH; Chen HM; Lin JW; Hsu CC; Lin SC; Hwang JS; Yang RS; Wu CH; Wang CY
    J Formos Med Assoc; 2023; 122 Suppl 1():S55-S64. PubMed ID: 37302970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Access to Anti-osteoporosis Medication after Hip Fracture in Korean Elderly Patients.
    Yu YM; Lee JY; Lee E
    Maturitas; 2017 Sep; 103():54-59. PubMed ID: 28778333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mortality and direct medical costs of osteoporotic fractures among postmenopausal women in Taiwan.
    Chang CY; Tang CH; Chen KC; Huang KC; Huang KC
    Osteoporos Int; 2016 Feb; 27(2):665-76. PubMed ID: 26243356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture.
    Weaver J; Sajjan S; Lewiecki EM; Harris ST; Marvos P
    J Manag Care Spec Pharm; 2017 Apr; 23(4):461-471. PubMed ID: 28345441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A national study on long-term osteoporosis therapy and risk of recurrent fractures in patients with hip fracture.
    Hsu CL; Chen HM; Chen HJ; Chou MY; Wang YC; Hsu YH; Liang CK; Chu CS
    Arch Gerontol Geriatr; 2020; 88():104021. PubMed ID: 32058125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan.
    Johnson B; Lai EC; Ou HT; Li H; Stollenwerk B
    Arch Osteoporos; 2021 Oct; 16(1):155. PubMed ID: 34636982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constraining in reimbursement criteria and the adherence to anti-osteoporosis medications (AOMs) in Taiwan: Urbanization makes the difference.
    Wang CY; Yang TH; Fu SH; Hwang JS; Chen HM; Lin JW; Hsu CC; Chang YF; Wu CH; Chan DC; Yang RS
    J Formos Med Assoc; 2023; 122 Suppl 1():S45-S54. PubMed ID: 37271714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.